trending Market Intelligence /marketintelligence/en/news-insights/trending/2Y_iZisSSA4a4SwKGJQCdw2 content esgSubNav
In This List

Nordic Nanovector lymphoma drug shows positive results in phase 1/2 study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Nordic Nanovector lymphoma drug shows positive results in phase 1/2 study

Nordic Nanovector ASA said that Betalutin drug for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma and follicular lymphoma demonstrated statistically significant results in ongoing phase 1/2 clinical study.

For relapsed/refractory indolent non-Hodgkin lymphoma, Betalutin as a single agent showed a reduction in tumor size in 90% of the patients. The drug demonstrated an overall response rate of 60% and a complete response rate of 24% in all evaluable patients.

Patients with follicular lymphoma were divided into two arms: the first arm demonstrated a 68% overall response rate and a 28% complete response, while the second arm had a 50% overall response rate and a 25% complete response.

The drug was highly active in patients with third stage follicular lymphoma who have received prior therapies and a 66% overall response rate and a 25% complete response was recorded.

The drug showed no safety concerns and was well-tolerated.